Completed PHASE2 INTERVENTIONAL 10-arm NCT03361956

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)Ide Analog in Subjects With Chronic Hepatitis B Virus Infection

Sponsor: Janssen Sciences Ireland UC

Conditions Hepatitis B

Interventions JNJ-56136379 NA (ETV or TDF) Placebo

Updated 38 times since 2017 Last updated: Oct 24, 2022 Started: Feb 13, 2018 Primary completion: Sep 5, 2019 Completion: Aug 13, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hepatitis B and is currently completed. Janssen Sciences Ireland UC leads this study, which shows 38 recorded versions since 2018 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

38 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE2
Sep 2025 — Dec 2025 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2022 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 33 earlier versions

Apr 2022 — Dec 2022 [monthly]

Completed PHASE2
Sep 2021 — Apr 2022 [monthly]

Completed PHASE2
Jan 2021 — Sep 2021 [monthly]

Completed PHASE2
Oct 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Sep 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE2
Aug 2020 — Sep 2020 [monthly]

Active Not Recruiting PHASE2
Jul 2020 — Aug 2020 [monthly]

Active Not Recruiting PHASE2
Jun 2020 — Jul 2020 [monthly]

Active Not Recruiting PHASE2
May 2020 — Jun 2020 [monthly]

Active Not Recruiting PHASE2
Apr 2020 — May 2020 [monthly]

Active Not Recruiting PHASE2
Mar 2020 — Apr 2020 [monthly]

Active Not Recruiting PHASE2
Feb 2020 — Mar 2020 [monthly]

Active Not Recruiting PHASE2
Jan 2020 — Feb 2020 [monthly]

Active Not Recruiting PHASE2
Dec 2019 — Jan 2020 [monthly]

Active Not Recruiting PHASE2
Nov 2019 — Dec 2019 [monthly]

Active Not Recruiting PHASE2
Sep 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE2
Aug 2019 — Sep 2019 [monthly]

Active Not Recruiting PHASE2
Jun 2019 — Aug 2019 [monthly]

Active Not Recruiting PHASE2
May 2019 — Jun 2019 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Apr 2019 — May 2019 [monthly]

Recruiting PHASE2
Mar 2019 — Apr 2019 [monthly]

Recruiting PHASE2
Feb 2019 — Mar 2019 [monthly]

Recruiting PHASE2
Jan 2019 — Feb 2019 [monthly]

Recruiting PHASE2
Dec 2018 — Jan 2019 [monthly]

Recruiting PHASE2
Nov 2018 — Dec 2018 [monthly]

Recruiting PHASE2
Oct 2018 — Nov 2018 [monthly]

Recruiting PHASE2
Sep 2018 — Oct 2018 [monthly]

Recruiting PHASE2
Aug 2018 — Sep 2018 [monthly]

Recruiting PHASE2
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE2
May 2018 — Jun 2018 [monthly]

Recruiting PHASE2
Mar 2018 — May 2018 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2018 — Mar 2018 [monthly]

Not Yet Recruiting PHASE2
Dec 2017 — Jan 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Sciences Ireland UC

Data source: Janssen Sciences Ireland UC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alor Star, Malaysia , Antwerp, Belgium , Bakersfield, United States , Bangkok, Thailand , Barcelona, Spain , Beijing, China , Berlin, Germany , Brussels, Belgium , Busan, South Korea , Calgary, Canada and 57 more locations